Why Empagliflozin’s Cardiovascular Benefit May Start in Your White Blood Cells

Coverage, in order

1. 13d ago
   
   Rapamycin News obscure

   Why Empagliflozin’s Cardiovascular Benefit May Start in Your White Blood Cells

   Sixteen women who were obese and had blood sugar levels on the edge of diabetes took empagliflozin, a common diabetes drug, every day for twelve weeks. Doctors drew their blood three times: before they started, after two weeks, and at the end. They were looking for a particular troublemaker in the…

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.